Abstract Number: 56

The efficacy of Janus Kinase (JAK) inhibitors in treating atopic dermatitis: a systematic review

C. J. Arora 1,2 , S. Shumack3

Meeting: 2021 Dermcoll

Session Information

Date: -

Session Title: Poster Presentations

Session Time: -

Background: Atopic dermatitis (AD), also known as eczema or atopic eczema, is a chronic, non-contagious, recurring inflammatory skin disease affecting both adults and children. Janus kinase (JAK) inhibitors are one of the drugs that its efficacy in treating AD has been studied. While most existing primary studies support the efficacy of JAK inhibitors, a major limitation of their results is a small sample size hence limiting generalizability of their results. Hence, the aim of this study is to determine the efficacy of JAK inhibitors in treating atopic dermatitis.

Methods: A systematic review was conducted. Four data- bases were searched; namely: PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Clinical.gov and WHO ICTRP. Hand searching was also done to identify rel- evant studies.

Results: 513 studies were identified. These studies were scrutinized against the inclusion and exclusion criteria.
504 studies were excluded due to various reasons. 9 stud- ies were included in the systematic review.

Conclusion: JAK inhibitors appear to be effective in treat- ing atopic dermatitis. Future studies should aim to evalu- ate its cost-effectiveness and availability to patients especially in developing countries.